GlaxoSmithKline Consumer Healthcare
Share-swap deal is favourable for shareholders
- HUL is acquiring 100% stake in GSK Consumer in all-equity deal of 4.39 HUL shares for every one share held by the shareholders of GSK Consumer, resulting in a deal value of Rs. 31,700 crore.
- The share-swap deal is positive for the shareholders of GSK Consumer, as they are getting HUL’s shares at a discounted rate (of Rs. 95-100 per share) in view of the current valuations of HUL.
- Further, GSK Consumer has strong cash balance of Rs. 3,800 crore, which we expect will be distributed among shareholders post the merger (HUL’s past five years’ dividend payout is ~83%).
- Hence, we advise investors to stay invested in GSK Consumer to create value post the merger (expected to complete in a year’s time).
- We maintain our Hold rating on GSK Consumer with a revised PT of Rs. 7,931.
Sun Pharmaceutical Industries
SEBI Investigation outcome an overhang; Downgrade to Hold
- Sun Pharma continues to remain surrounded by issues, the recent one being a whistle blower case filed with SEBI.
- Related party structure raises concerns among investors.
- We downgrade our recommendation to Hold with downward revised PT of Rs. 525.
Banking sector me kya krna hair much batao sir
ReplyDeleteSir, fiber companies me uptrend aayega ya loss lekar bahar ho jau.
ReplyDeleteAgar long term me invest kiya hair to wait karo or short term hai to loss kam kar Ke bahar ho jao. 😊
ReplyDelete